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The antigens encoded in the HLA-D region of the human major histocompat- 
ibility complex (MHC) 1 were originally defined with homozygous typing cells by 
mixed leukocyte culture and, subsequently, by use of human alloantisera reacting 
with antigens selectively expressed on B cells (1,  2).  These antigens were later 
shown  to  be  the  human  equivalents of the  murine  Ia  molecules.  The  major 
serologically defined specificities, called DR, were found to be closely associated 
with the specificities defined by HTCs.  Later, the development of ailoantisera 
permitted identification of additional serologic specificities such as DC, MB, MT, 
and Te (3-8) which are not associated with a  single DR specificity but, instead, 
are  found associated  with  two  or  more  DR  alleles and  are,  therefore,  called 
supertypic.  For  example,  MT2  is  usually  found  on  DR3-,  DR5-,  DRw6-,  or 
DRw8-bearing cells while MT3  is  usually found on cells from DR4-,  DR7-,  or 
DRwg-positive  donors.  The  apparent  equivalence  of terms  used  by  different 
investigators is shown in Table I (see also reference 3). 
Studies of the structural bases for these serological specificities have focused 
on three types of molecules that have been described biochemically. In a total Ia 
isolate, DR molecules are the predominant set of HLA-D region antigens and are 
homologues  of the  murine  I-E  molecules  (9).  These  molecules  bear  the  DR 
serologic specificities, which have been shown to be associated with their poly- 
morphic beta chains (9). A DR homozygous cell line expresses DR molecules that 
are a  set of closely related proteins which appear to share a  single alpha chain 
and possess several structurally distinct beta chains (10,  1 1). It is not clear if all 
of these  1-E-like species carry the  DR  serologic determinants that are defined 
with  alloantisera.  The  DS  (DC)  antigens are  homologues  of the  murine  I-A 
antigens (12) and bear the MB serologic determinants (13,  14).  There may be 
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TABLE  I 
Supertypic Series of HLA-D Region Antigens 
473 
MB Series  MT Series 
MB  Associated  DR  Equivalent  MT  Associated  DR  Equivalent 
specificities  specificities  specificities  specificities 
MBI  DR1,2, w6, wl0  DC1,Te21,MT1  MT1  DR1,2, w6, wl0  DC1,Te21,  MB1 
MB2  DR3,  7  DC3, Te24  MT2  DR3,  5, w6, w8  (BR3)* 
MB3  DR4,  5, w9  DC4, Te22, MT4  MT3  DR4,  7, w9  (BR4)* 
* Molecules bearing MT2 and MT3 determinants have been called BR3 and BR4, respectively  (20, 
24). 
two different kinds of DS molecules expressed by a DR homozygous cell line but 
only one may carry MB determinants (15 and R. G. Giles, R. DeMars, andJ. D. 
Capra, unpublished results). The third set of HLA-D region antigens are the SB 
antigens  which  are  intermediate  in  homology  with  the  murine  I-A  and  I-E 
antigens and are distinct from both DR and DS antigens (16-18). 
The  nature  of the HLA-D  region  molecules that  bear  the  MT2  and  MT3 
supertypic specificities has been controversial. Two-dimensional gel electropho- 
resis and peptide mapping have identified MT determinants on DR molecules 
(19-22), on DS molecules (21,  22), and even on a  third set of molecules related 
to, but distinct from, DR and DS, sometimes termed BR (20, 23, 24). In addition, 
two studies have shown that there may be a sharing of MT serologic determinants 
between  DR and  DS  molecules (21)  and between  DR and BR  molecules (20). 
Three different constructs have emerged from these studies to explain the MT2 
and MT3 specificities: (a) MT2 and MT3 reside on DR molecules, (b) MT2 and 
MT3  reside on DS molecules, and (c) MT2 and MT3  reside on molecules that 
are distinct from DR and DS, and are the products of an additional locus. Since 
the  majority of studies  used complex  alloantisera in  their analyses, additional 
reactivities directed against specificities other than MT might have added to the 
number of molecules observed. 
Monoclonal antibodies directed against MT2- and MT3-1ike supertypic speci- 
ficities were used in this study to define the molecules bearing these specificities 
from a  set of cell lines. MT2- and MT3-bearing molecules have been compared 
with DR, DS, and, in some instances, SB molecules derived from the same cell 
line using inhibition of cell surface fluorescence or cytotoxicity, as well as amino 
acid  sequence  analysis  and  peptide  mapping.  The  data  show  that  the  major 
populations of molecules bearing MT2 and MT3 determinants are indistinguish- 
able from DR molecules. 
Materials and Methods 
Monoclonal Antibodies.  The murine monoclonal antibodies with MT-like specificities, 
I-LR2 (25) and 109d6 (26, 27), have been previously defined. Monoclonal antibody L203 
recognizes monomorphic determinants present on all B cell lines. By amino acid sequence 
analysis, the molecules recognized by L203 are homologous to murine 1-E antigens and 
have been termed DR for this reason (28). Monoclonal antibody L203 blocks many anti- 
DR alloantisera, suggesting that it recognizes molecules bearing the serologically defined 
DR specificities (29, 30). The monoclonal antibody IIIE3 recognizes a subset of the L203- 
reactive antigens which, by sequence analysis of the reactive molecules, has been identified 474  MOLECULAR LOCALIZATION OF MT2 AND MT3 
as DR-like (28). Additional binding studies using HLA deletion mutants suggest that L203 
and IIIE3 are directed against framework determinants of DR antigens (31).~ Monocional 
antibody  I-LR1  recognizes  SB  antigens;  however,  in  a  DR5  cell  it  also  binds  to  DR 
molecules (C.  K.  Hurley and S.  Shaw,  unpublished  results).  The monoclonal antibody 
IVD12 is specific for the MB3 supertypic specificity and primarily detects DS molecules 
on both DR4 and DR5 cell line~ (13, 32). SFR3-DR5, a DRS-specific monoclonal antibody, 
was a  gift  from  Dr.  Susan  Radka  (33).  Monoclonal  antibody  7.3.19.1,  a  monoclonal 
antibody with an MT2-binding pattern,  was a gift from Frits Koning (34).  Monoclonal 
antibody 61 D2 is directed against HLA-A, B, C antigens (35). Monoclonal antibody L368, 
directed against/32-microglobulin, was a gift from Dr. Ron Levy. 
Cell Lines.  721.127 (DR3) is a B lymphoblastoid cell line bearing only one copy of the 
MHC  because  the  other  copy was  physically deleted  by  means  of ~,  irradiation  (31). 
PRIESS (DR4) has been described (36). Cell lines GM3105A (DRS), GM3164 (I)R4), and 
GM3163  (DR7)  were from the  Human  Genetic Mutant  Cell  Repository, Camden,  NJ. 
113w7  (DR7) and DHI (DR5) were gifts from Dr. Mary Ann Robinson. YBE (DR3) was a 
gift from Dr. John Sachs. 
B Cell Panel.  Peripheral blood B cells from members of the tissue-typing laboratory 
reference  panel  were  screened  by  indirect  immunofluorescence  for  the  presence  of 
I-LR2- or 109d6-reactive cell surface antigens. Reactivity with I-LR2, 109d6, or control 
monoclonal antibodies was determined by counting positive cells in a fluorescence micro- 
scope equipped with epifluorescence optics. The HLAoDR, MB, and MT phenotype of 
the cells used in the B cell pane] had been previously determined by microcytotoxicity 
using typing reagents from the Eighth International Histocompatibility Workshop, as well 
as local alloantisera. Likewise, B cells from several informative families were examined by 
fluorescence for their ability to bind I-LR2 and 109d6. 
Preparation  of Fluorescein-conjugated  Monoclonal  Antibodies.  Monoclonal  antibodies 
I-LR2 and  L203  were isolated by ammonium sulfate fractionation followed by DEAE° 
Sephadex chromatography. This material was then conjugated with fluorescein isothio- 
cyanate and made up to a protein concentration of 1 mg/ml (37). 
Fluorescence  Inhibition  Experiments.  Cells  (1  x  10  ")  from  the  B  cell  lines  DHI, 
GM 3105A, and 721.127 were suspended in 100 zl of a saturating concentration of ascites 
(1:50) containing various monoclonal antibodies except SFR3-DR5, which was used as a 
5x concentrate of culture supernatant. Except for control antibodies and antibodies with 
polymorphic specificities, all antibodies were shown to bind to GM3105A,  DHI, and/or 
721.127  by indirect  immunofluorescence.  The exceptions were shown by indirect  im- 
munofiuorescence to bind to the appropriate cells.  Briefly, cells were incubated with the 
monoclonal antibodies, washed, and stained with fluoresceinated rabbit anti-mouse IgG 
(Cappel  Laboratories,  Cochranville,  PA).  The  stained  cells  were  examined  using  the 
fluorescence-activated cell sorter (FACS III; B-D FACS Systems, Sunnyvale, CA). To test 
for  inhibition,  the  cells  were  incubated  for  30  min  at  4°C  with  various  monoclonal 
antibodies and washed twice with cold RPM1  1640 containing 0.1% sodium azide. After 
incubation with 100 #1 of a  1:20 dilution of fluoresceinated I-LR2, the cells were washed 
twice and analyzed in the FACS. 
Attoantisera.  Alloantisera specific for the specificities MT2 (9w688  from H. Festen- 
stein, 9w689 and 9w699 from D. Woodfield), MT3 (9w733 from M. Fotino, 9w734 from 
J.  Dausset, 9w743  from N. Suciu-Foca), DR4 (9w575 from P. Terasaki), DR7 (9w630), 
and DR5 (9w597 from H. Betuel and 9w603 from D. Singal) were obtained as part of the 
Ninth  International  Workshop serum  exchange.  All  of these  sera  were  tested  in  our 
laboratory with a  panel of B cells  from at least 75  individuals and were found to have 
high correlation (r >  0.8) with their given specificities. 
Lymphocytotoxicity Inhibition.  To test the ability of monoclonal antibodies L203, I-LR2, 
IVD12,  and  109d6  to  inhibit  the  cytotoxic activity of specific alloantisera,  cells  were 
precoated  with  monoclonal  antibody  before  performing  the  cytotoxicity  assay.  Cells 
incubated with L368, a monoclonal antibody reactive with/32-microglobulin, were used 
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as negative controls. Briefly, cells (4  ×  106/ml) were incubated with an equal volume of 
monocional antibody (ascites at a  1:100  dilution) for 30 min at room temperature and 
washed in RPMI  1640 medium. After a  15 min incubation with an F(ab')2 fragment of a 
sheep anti-mouse IgG antibody (Cappel  Laboratories) at room temperature,  cells were 
washed  and  suspended  in  RPMI  containing  10%  fetal  calf serum.  Cytotoxicity  was 
performed  according  to  the  standard  NIH  complement-dependent  microcytotoxicity 
method using MT- and  DR-specific alloantisera.  Percent lysis was determined by eosin 
dye exclusion using an inverted microscope. 
Isolation of Radiolabeled Antigens.  Cells  were radiolabeled  with  3H-amino acids and 
lysed with Nonidet P-40. A glycoprotein pool was affinity purified on a lentil lectin column 
as previously described (28). Briefly, the HLA-D region antigens were isolated by passage 
of the glycoprotein pool over antibody affinity columns using either 0.05 M diethylamine 
or  1.5  M  ammonium thiocyanate for elution.  For some studies,  radiolabeled antigens 
were isolated by immunoprecipitation. In these experiments, an immunoglobulin-depleted 
pool was incubated with monoclonal antibody either in the form of an ammonium sulfate 
fraction or 10 times concentrated culture supernatant. Rabbit or goat anti-mouse immu- 
noglobulin  (Cappel  Laboratories)  was added  and  the  immune  complexes removed by 
centrifugation. Alpha and beta polypeptide chains were isolated from the purified antigens 
using preparative sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
under reducing conditions (28). 
Amino Acid Sequence Determination and Peptide Mapping.  Sequential  Edman degrada- 
tion of isolated alpha and beta chains labeled with a single 3H-amino acid was performed 
using  Beckman  890C  and  890D  amino  acid  sequencers  (Beckman  Instruments,  Inc., 
Fullerton, CA) (28). The resultant butyl chloride fractions were monitored for radioactiv- 
ity using a scintillation counter. 
For peptide mapping, ~5  ×  104 cpm of an isolated chain plus a protein carrier were 
dialyzed against water to remove excess SDS, lyophilized to dryness, and redissolved in 
0.1  M ammonium bicarbonate. 50 ~g of trypsin (TPCK-Trypsin; Worthington Biochem- 
ical Corp., Freehold, NJ) were added and the reaction mixture incubated at 37°C for 3 
h.  Fresh  trypsin was added  and the digestion continued overnight. The peptides were 
separated  using  a  Waters  higb  performance  liquid  chromatograph  equipped  with  a 
MicroBondapak C18 column (Waters Associates Inc., Milford, MA). A linear gradient of 
0.02%  trifluoroacetic acid and 70% acetonitrile/30%  isopropanol was used to elute the 
peptides. Aliquots from the gradient were examined for radioactivity as above. 
Affinity Chromatography of Column Eluates.  Several experiments were performed to 
assess the reactivity of certain antigens with two different monoclonal antibodies. These 
experiments were designed to determine the degree of "uniqueness" vs. "overlap" of MT 
and DR specificities. Such experiments were performed with several cell lines (721.127, 
I13w7, and GM3163) and the I-LR2 (MT2),  109d6 (MT3) and L203 (DR) monoclonal 
antibodies. A typical experiment comparing L203 and I-LR2 is described. A glycoprotein 
pool from the cell line 721.127 was chromatographed on a L203 antibody affinity column. 
Protein carrier was added to the eluate containing the L203-reactive antigens and, after 
dialysis to remove the elution buffer, the eluate was sp[it into three a[iquots. One aliquot 
was repassed over the L203 column, one aliquot was passed over an I-LR2 affinity column, 
and the third aliquot was passed over an irrelevant antibody column. The eluates from 
the three columns were dialyzed and examined by SDS-PAGE. Estimates of counts bound 
were made by totalling the area under the alpha and beta chain peaks from the gels. The 
reverse experiment using an  I-LR2 eluate was performed as above.  In the case of the 
109d6/L203 comparisons, estimates of the counts bound were determined by measuring 
the radioactivity in each column eluate. 
Results 
Monoclonal  Antibodies  Recognize  MT2-  or  MT3-like  Supertypic  Specifici- 
ties.  Monoclonal  antibody  I-LR2,  when  tested  on  homozygous  typing  cells, 
exhibited an MT2-specific pattern of binding (25). Further studies using periph- 476  MOLECULAR LOCALIZATION OF MT2 AND MT3 
TABLE  II 
Correlation Between HLA-D Region Phenotype and I-LR2 Reactivity from a 
B Cell Panel of 72 Donors 
Phenotype  +/+*  +/-  -/+  -/-  X  e  r 
DR1  11  7  28  26  0.167  0.048 
DR2  8  13  32  19  2,700  -0.194 
DR3  20  0  19  33  20.945  0,539 
DR4  13  17  28  14  2.992  -0.203 
DR5  13  0  26  33  11.265  0,395 
DRw6  9  0  30  33  6.721  0,305 
DR7  1  6  38  27  3.347  -0,215 
DRw8  1  6  39  26  3.657  -0.225 
DRw9  1  0  38  33  0,007  0,009 
DRwl0  0  5  40  27  4.516  -0.250 
MB1  22  21  18  11  0.451  -0.079 
MB2  21  6  19  26  7.260  0,317 
MB3  23  18  17  14  0.017  0,015 
MT2  40  6  0  26  47.408  0.811 
MT3  15  18  25  14  1.818  -0.158 
DR3 +  5 +  w6  38  0  0  34  68,043  0,972 
X  2 with Yates' correction; r values were obtained using the formula r = 
and the positive or negative correlation by the formula ad =  bc. 
Presence of HLA-D region phenotype/I-LR2 reactivity by immunofluorescence. 
eral blood B lymphocytes from a panel of 72 normal individuals confirmed this 
specificity (Table II). I-LR2 bound to cells bearing DR specificities 3, 5, and w6, 
which are included in the MT2 supertypic specificity, with a correlation of 0.811. 
Note that  I-LR2 did not react with most DRw8 cells although  all  of the DRw8 
cells had been typed as MT2 positive with alloantisera.  If only DR3, 5, and w6 
are considered, the combined correlation  with I-LR2 reactivity is 0.972 (Table 
II). A similar specificity pattern has been observed for an independently derived 
MT2-1ike monoclonal antibody, 7.3.19.1 (34). Segregation of the I-LR2-reactive 
determinant  with  DR3  and  DR5  was observed in  two potentially  informative 
families. The inheritance of I-LR2 in one of those families is illustrated in Table 
III. As indicated in one family (Deh, Table III), I-LR2 binding was inherited in 
parallel  with  reactivity to DR3 and  MT2 alloantisera;  in a  second family (data 
not shown), I-LR2 binding was inherited  in parallel  with reactivity to DR5 and 
MT2 alloantisera. 
The specificity of the monoclonal antibody  109d6 as MT3 has been defined 
using  homozygous  typing  cells  (26,  27,  38).  Studies  on  peripheral  blood  B 
lymphocytes from normal and diseased patients supported this assignment (26, 
27,  38).  Additional  panel  testing  on  20  normal  individuals  and  38  patients 
further confirmed the specificity of the antibody (Table IV).  Every donor who 
was typed positive for MT3 reactivity using a|loantisera was positive for  109d6 
reactivity. Six donors that were MT3 negative also reacted with 109d6. This was 
due to the binding of 109d6 to DRwl0-bearing cells. The correlation of 109d6 
reactivity with MT3, therefore, was 0.768. However, when DRwl0 binding was 
added into the calculation (Table IV), the correlation became 0.96 i. Additional 
experiments are being performed to determine the nature of the target antigen HURLEY  ET  AL. 
TABLE  III 
Segregation of I-LR2 and 109d6 Reactivity with HLA in Families 
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Family  HLA genotype  Haplo-  Reactivity 
member  A, B, C  DR  MB  MT  types  1-LR2  109d6 
Deh  Father  1, w57, w6  7  2  3  a  +  + 
w24, w38, -  3  2  2  b 
Mother  l, w44, w5  4  3  3  c  -  + 
w24, 7, w7  4  3  3  d 
Sib 1  1, w57, w6  7  2  3  a  -  + 
w24, 7, w7  4  3  3  d 
Sib 2  1, w57, w6  7  2  3  a  -  + 
1, w44, w5  4  3  3  c 
Sib 3  w24, w38, -  3  2  2  b  +  + 
1, w44, w5  4  3  3  c 
Sib 4  w24, w38, -  3  2  2  b  +  + 
w24, 7, w7  4  3  3  d 
Her  Father  w24, w35, w4  5  3  2  a  +  - 
28, -, w3  5  3  2  b 
Mother  w24, 18,-  5  3  2  c  +  + 
w24, w61, w3  4  3  3  d 
Sib 1  28, -, w3  5  3  2  b  +  - 
w24, 18,-  5  3  2  c 
Sib 2  28, -, w3  5  3  2  b  +  - 
w24, 18, -  5  3  2  c 
Sib 3  28, -, w3  5  3  2  b  +  + 
w24, w61, w3  4  3  3  d 
Sib 4  28, -, w3  5  3  2  b  +  + 
w24, w61, w3  4  3  3  d 
Sib 5  w24, w35, w4  5  3  2  a  +  - 
w24,  18, -  5  3  2  c 
recognized by  109d6 on cells from DRwl 0-positive donors. The inheritance of 
109d6 with HLA haplotypes is shown in Table III. 
To further support the conclusion that I-LR2 and 109d6 recognize determi- 
nants associated with the MT2 and MT3  supertypic specificities, the ability of 
the monoclonal antibodies to block cytotoxicity of MT-specific alloantisera was 
examined with both B cell lines and normal B ceils. The results of some of these 
studies are  shown in TablesV,  VI, and VII.  Table  V  compares the ability of 
I-LR2  to  block  MT2-specific  alloantisera  to  that  of the  anti-DR  monoclonal 
antibody L203. While L203 was able to block the three MT2 alloantisera in all 
combinations, I-LR2 was only able to block partially two of the three MT2 sera. 
I-LR2, in contrast to L203, was unable to block alloantisera directed against DR 
specificities. IVD 12, an anti-DS (MB3) monoclonal antibody, did not block DR- 
or MT2-directed cytotoxicity. 
Tables VI and VII illustrate similar experiments with MT3 alloantisera and 
monoclonal antibody 109d6. In the DR4 cell line, L203 inhibited both DR4 and 
MT3 cytotoxicity; 109d6 only inhibited MT3 alloantisera killing in some but not 
all circumstances. In the DR7  cell line GM3163,  L203 blocked cytotoxicity of 
all  MT3  alloantisera.  However,  109d6  only weakly blocked one of the  three 478  MOLECULAR LOCALIZATION  OF MT2 AND MT3 
TABLE  IV 
Correlation Between HLA-D Region Phenotype on B Cells and I09d6 Reactivity 
from a B Cell Panel of 58 Donors 
Phenotype  +/+*  +/-  -/+  -/-  X  2  r 
DR1  2  !  37  18  0.365  0,078 
DR2  5  6  33  14  1.446  -0.157 
DR3  5  6  33  14  1.446  -0.157 
DR4  17  0  21  20  10.590  0.427 
DR5  9  6  29  14  0.042  -0.026 
DRw6  4  12  34  8  13.674  -0.485 
DR7  12  0  26  20  6.155  0.325 
DRw8  3  3  35  17  0.152  -0.051 
DRw9  3  1  35  19  0,017  0.017 
DRwI0  6  0  32  20  2,025  0.186 
MB1  21  17  17  3  3.897  -0.259 
MB2  18  5  20  15  1.884  0.180 
MB3  19  3  19  17  5.412  0.305 
MT2  23  20  15  0  8,689  -0.387 
MT3  32  0  6  20  34.243  0.768 
DR4 +  7 +  w9 +  wl0  38  0  0  20  53.658  0.961 
X  2 with Yates' correction; r  values were obtained using the formula r  =  ~/x2/n and 
the positive or negative correlation by the formula ad =  bc. 
Presence of HLA-D region phenotype/109d6 reactivity by immunofluorescence. 
TABLE  V 
Inhibition  of DR5 and MT2 Alloantisera  by Monoclonal  Antibodies  in DHI (DR5) 
Cytotoxicity scores* 
9w597  9w603  9w688  9w689  9w699 
(DR5)  (DR5)  (MT2)  (MT2)  (MT2) 
Blocking  Specificity  Serum  Alloantisera 
antibody  dilution 
L368  ¢~2-microglobulin 
L203  DR 
IVDl2  MB3 
I-LR2  MT2 
Und  8  8  8  8  8 
1:2  8  6  8  6  8 
1:4  8  1  8  1  8 
1:8  1  1  1  1  4 
Und  1  1  1  1  4 
1:2  1  1  1  1  1 
1:4  1  1  1  1  1 
Und  8  8  8  8  8 
1:2  8  6  8  6  8 
1:4  8  1  6  1  8 
1:8  1  1  1  1  1 
Und  8  8  8  4  8 
1:2  8  6  6  1  8 
1:4  8  1  1  1  8 
1:8  1  1  1  1  1 
* Cytotoxicity reactions were recorded as follows: 8, >81%  tysis; 6,  51-80%  lysis; 4, 21-50%  lysis; 
2,  11-20% lysis; 1, <11% lysis. HURLEY  ET  AL.  479 
TABLE  VI 
Inhibition  of DR4 and MT3 Alloantisera  by Monoclonal Antibodies in Priess (DR4) 
Cytotoxicity scores* 
9w575  9w630  9w733  9w734  9w743 
(DR4)  (DR7)  (MT3)  (MT3)  (MT3) 
Blocking  Specificity  Serum  Alloantisera 
antibody  dilution 
L368  /32-microglobulin  Und  8  1  8  8  8 
1:2  8  1  1  8  8 
1:4  8  1  1  8  8 
1:8  1  1  1  8  6 
1:16  1  1  1  1  1 
L203  DR  Und  1  1  1  8  1 
1:2  1  1  1  6  1 
1:4  1  1  1  1  1 
1:8  1  1  1  1  1 
IVD12  MB3  Und  8  1  8  8  8 
1:2  8  1  I  8  8 
1:4  8  1  1  8  8 
1:8  1  1  1  6  1 
109d6  MT3  Und  8  1  8  8  2 
1:2  8  i  1  8  1 
1:4  8  1  1  1  1 
1:8  1  1  1  1  1 
* Cytotoxicity reactions were recorded as follows: 8, >81%  lysis; 6, 51-80%  lysis; 4,  21-50%  lysis; 
2,  11-20% lysis; 1, <11%  lysis. 
MT3  alloantisera.  Results with  normal  B  cells  were  in agreement with these 
findings  (data  not  shown).  Note  that  while  109d6  was  able  to  block  MT3 
alloantiserum 9w743  cytotoxicity in the DR4 line, it had no effect in the DR7 
line. This suggests that the serum may have some anti-DR7 reactivity or that the 
relationship of the  109d6 determinant to the MT3 determinant is different in 
DR4 and DR7 cells.  The anti-DS antibody IVD12, again, did not block either 
DR- or MT3-directed cytotoxicity. 
Some Monoclonal Antibodies Block  MT2- or MT3-Specific Binding.  A  panel of 
monoclonal antibodies was used to inhibit the binding of fluoresceinated I-LR2 
(anti-MT2)  to  DR3  (721.127)  or  DR5  (GM3105A  and  DHI)  cell  lines.  The 
amounts of this inhibition are presented in Table VIII. When tested on the DR5 
cell lines, I-LR2 completely inhibited fluoresceinated I-LR2 while an irrelevant 
antibody (61D2, an anti-HLA-A, B, C monoclonal antibody) did not inhibit the 
binding. SFR3-DR5, the anti-DR5 monocional antibody, and to a lesser extent, 
L203, inhibited I-LR2, while IVD12, an anti-DS monoclonal antibody, did not 
inhibit its binding. In studies using the DR3 cell line, the results obtained with 
the monoclonai antibodies excluding IVD12  and  I-LR1  were similar.  IVD12, 
SFR3-DR5, and I-LR1  do not bind to the DR3 cell line. Monoclonal antibody 
7.3.19.1, an independently derived antibody with an MT2-1ike binding pattern 
(34),  completely blocked  I-LR2  binding on  the  DR3  line  but  inhibited  only 480  MOLECULAR LOCALIZATION  OF MT2 AND MT3 
TABLE  VII 
Inhibition  of MT3 Alloantisera  by Monoclonal  Antibodies  in the B Cell Line GM3163 (DR7) 
Cytotoxicity scores* 
Blocking  Specificity  Serum  Alloantisera 
antibody  dilution 
9w575  9w630  9w733  9w734  9w743 
(DR4)  (DR7)  (MT3)  (MT3)  (MT3) 
L368  /32-microglobulin  Und  1  8  8  8  8 
1:2  1  8  8  8  8 
1:4  1  8  1  8  6 
1:8  1  2  1  1  1 
L203  DR 
IVD12  MB3 
Und  1  1  6  1  1 
1:2  1  1  I  1  1 
1:4  1  1  1  1  1 
Und  1  8  8  8  8 
1:2  1  8  8  8  8 
1:4  1  8  2  8  8 
1:8  1  2  1  2  1 
Und  1  8  8  8  8 
1:2  1  8  8  8  8 
1:4  1  8  1  1  8 
1:8  1  1  1  1  1 
109d6  MT3 
* Cytotoxicity reactions were recorded as follows: 8, >81%  lysis; 6,  51-80%  lysis; 4, 21-50%  lysis; 
2,  11-20% lysis; 1, <11%  lysis. 
weakly in the two DR5 cell lines tested. Strong inhibition was found in the DR5 
lines,  however, when  a  second antibody (goat anti-mouse  Ig) was used before 
adding  fluoresceinated I-LR2 (data not shown).  This suggests that  monoclonal 
antibody 7.3.19.1  detects a  determinant  on the DR5 lines that  is distinct  from 
the I-LR2 determinant  but on the same molecule. I-LR1  strongly inhibited the 
binding of I-LR2 to the  DR5 cell line.  The inhibition  of I-LR2 by I-LR1  in a 
DR5  line  is  not  entirely  unexpected  since  I-LR1  is  known  to  recognize  DR5 
molecules in  addition  to  SB2 and  SB3  molecules (C.  K.  Hurley and  S.  Shaw, 
unpublished observations). 
MT2 and MT3 Specificities Reside on DR-like Molecules.  The molecules reactive 
with either I-LR2 (MT2) or 109d6 (MT3) were isolated from DR3, DR4, DR5, 
or DR7 cell lines.  By SDS-PAGE,  I-LR2-reactive molecules,  like the DR mole- 
cules,  contained  two  polypeptide  chains,  while  the  109d6-reactive  molecules 
usually appeared as three peaks on the gel profile (Fig.  1). L203 and IIIE3 were 
used to isolate DR molecules from these cell lines. Partial amino-terminal  amino 
acid sequences of molecules reactive with all of these monoclonal antibodies were 
determined (Tables IX and X). Table IX compares the alpha chain sequences of 
MT and DR molecules from DR3, 4, 5, and 7 cell lines. Table X compares the 
beta chains from the same preparations.  Although  only the tyrosine and phen- 
ylalanine  residues are compared,  the predominant  sequences of the alpha  and 
beta chains of I-LR2- and 109d6-reactive molecules are identical to those derived 
using the anti-DR monoclonal antibodies. HURLEY  ET  AL,  481 
TABLE  VIII 
FAGS Analysis of the Inhibition of Fluorescein-conjugated I-LR2 by Various Monoclonal 
Antibodies 
B cell lines 
Blocking  Specificity  721.127  DHI  GM3105A 
antibody  (DR3)  (DRf)  (DRf) 
MFI*  %1:1:  MFI  %1  MFI  %1 
54.8  5  57.4  6  44~5  0 
61D2  HLA-A, B, C  56.9  0  59.3  0  43.8  0 
I-LR2  MT2  19.7  100  28.7  100  19.5  100 
L203  Monomorphic DR  49.7  27  49.5  32  36.1  32 
SFR3-DR5  DR5  59.8  0  35.9  76  23.6  83 
7.3.19.1  MT2  20.8  97  53.3  20  38.3  23 
IVDI2  MB3  52.9  11  63.2  0  47.7  0 
I-LR1  SB2, SB3, DR5  56.0  2  38.7  67  24.0  81 
* Mean fluorescence intensity (MFI) on 104 cells analyzed on FAGS. 
* Percent inhibition  calculated from the following formula: %I =  100 
MF1 [I-LR2I)/(MFI [61D2] -  MFI [I-LR2])]. 
t RPMI 1640 containing 10% human serum. 
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FIGURE  1.  SDS-PAGE profiles of molecules isolated from the cell line 721.127 using mono- 
clonal  antibodies (.4) I-LR2  and  (B)  L203/L243,  and  from  the  cell  line PRIESS  using 
monoclonal  antibodies  (C) 109d6 and (D) IIIE3. The arrows indicate the approximate positions 
of immunoglobulin  heavy and light chains. 
One of the more striking features of these sequence data is the ease with which 
one can distinguish each of the DR specificities with just the tyrosine sequences 
of the beta chains. Two cell lines were studied in each of four DR specificities. 
Note that both DR3 lines contain tyrosine at positions 10, 26, and 30; both DR5 482  MOLECULAR LOCALIZATION  OF MT2 AND MT3 
TABLE IX 
Amino-Terminal Amino Acid Sequence Data: Alpha Chains 
Monoclonal  Position 
Cell line 
antibody  12  13  22  24  26  32 
127 (DR3)  I-LR2  F  Y 
'¢BE (DR3)  V 
F  F  F  F 
127  L203"  F  Y  F  F  F  F 
YBE  Y 
3105(DR5)  I-LR2  F  Y  F  F  F  F 
DHI(DR5)  Y 
3105  L203  F  Y  F  F  F  F 
DHI  Y 
PRIESS (DR4)  109d6  F  Y  F  F  F  F 
3164 (DR4)  Y 
PRIESS  L203"  F  Y  F  F  F  F 
3164  Y 
I13w7 (DR7)  109d6  F  Y  F  F  F  F 
3163 (DR7)  Y 
I13w7  L203  F  Y  F  F  F  F 
3163  Y 
* Anti-DR monoclonal antibody IIIE3  was used in these experiments as 
well. 
lines contain  tyrosine at positions  10,  30, and  32;  both  DR4 cell  lines  contain 
tyrosine at  positions  30  and  32;  and  both  DR7  cell  lines  contain  tyrosine at 
positions 13 and 32. In every instance, the MT-bearing molecule has the identical 
sequence as the DR molecule. 
Minor sequences that  correspond to known  DS sequences were observed in 
some I-LR2 and,  to a  greater extent,  109d6 preparations.  Both DS alpha  and 
DS beta chain  sequences were observed.  In  the  example  shown  in  Fig.  2,  an 
alpha chain preparation  from a DR4 cell line contains two sequences, a predom- 
inant  DR sequence (tyrosine at position  13) and a  minor DS sequence (tyrosine 
at positions 11, 16, and 19). The DS population represents ~20% of the molecules 
present in this preparation.  The amount of DS sequence obtained with the MT 
monoclonal antibodies varied from preparation  to preparation and represented 
anywhere from 3 to 30% of the molecules present.  In general, when  109d6 was 
used with DR4 cell lines, approximately an 80:20 ratio of DR/DS molecules was 
detected, while in DR7 cell lines, the DR/DS ratio was closer to 95:5. 
The higher molecular weight peak found in the  109d6 preparations (Fig.  1  C) 
was identified as HLA-A/B by amino acid sequence. The preparation contained 
tyrosines  at  positions  7  and  27  and  sometimes  position  9,  corresponding  to 
previously characterized  class I  molecules (39).  This suggests that either  HLA- HURLEY  ET  AL. 
TABLE  X 
Amino-Terminal Amino Acid Sequence Data: Beta Chains 
483 
Cell line 
Monodonal  Position 
antibody  7  10  13  17  18  26  30  31  32 
127 (DR3)  I-LR2  F  Y  F  F  Y  Y 
YBE (DR3)  Y  Y  Y 
127  L203"  F  Y  F  F  Y  Y 
YBE  Y  Y  Y 
3105 (DR5)  I-LR2  F  Y  F  F  F  Y 
DHI (DR5)  Y  Y 
F 
3105  L203  F  Y  F  F  F  Y  F 
DH[  Y  Y 
PRIESS (DR4)  109d6  F  F  F  F  Y  F 
3164 (DR4)  Y 
PRIESS  L203"  F  F  F  F  Y  F 
3164  Y 
I13w7 (DR7)  109d6  F  Y  F  F  F 
3163 (DR7)  ND 
ND* 
F  I13w7  L203  F  Y  F  F  F 
3163  Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
*  Anti-DR monoclonal antibody IIIE3 was used in these isolations as well. 
* Not determined. 
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FIGURE 2.  Amino acid sequence profile of an [SH]tyrosine-labeled alpha chain isolated from 
the  cell  line  GM3164  esing  monoclonal  antibody  I09d6.  The  horizontal  axis  represents 
position in the protein sequence. 
A/B  molecules  carry  a  109d6  determinant  or  that  class  I  molecules  may  be 
complexed  with some  class II molecules. 
At Least Some Molecules  Carry Both  DR and MT Specificities.  To  examine  if 
I-LR2/109d6  and  L203  recognize  identical populations  of molecules, aliquots of 
molecules  reactive  with  one  of the  monoclonal  antibodies  were  passed  over  the 484  MOLECULAR LOCALIZATION OF MT2 AND MT3 
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FIGURE 3.  Tryptic  peptide  maps  of  [SH]tyrosine-labeled  beta  chains  from  the  cell  line 
721.127 isolated using monoclonal antibodies (,4) L203/L243 (B) L203/L243 and I-LR2, and 
(C) I-LR2. 
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FIGURE 4.  Tryptic peptide maps of [SH]phenylalanine-labeled beta chains from the cell line 
721.127 isolated using monodonal antibodies (A) I-LR2 and (B) L203. The elution gradient 
is indicated by the dotted line. 
same  affinity  column  and  the  complementary  column,  and  the  percentage  of 
bound counts estimated.  Although the percentages  were  variable,  it was clear 
that L203  recognized  a  large proportion of the molecules reactive  with  I-LR2 
or  109d6  antibodies.  In  the  reverse  experiment,  although  there  was  some 
variability,  in general  less than  half of the counts that bound and were  eluted 
from an  L203  affinity  column could be rebound to either an  I-LR2 or  109d6 
column. An irrelevant antibody column bound a negligible amount of radioactive 
material in all cases. These data suggest that at least some molecules carry both 
DR  and  MT  specificities,  but  some  molecules  carry  only  DR  specificities  (as 
defined by L203) and not MT specificities. 
Molecules  Bearing  the  MT2  Specificities  Are  Indistinguishable  from  DR  Mole- 
cules.  The alpha and beta chains of I-LR2-binding molecules from the DR3 cell 
line 721.127 were compared with L203-binding alpha and beta chains from the 
same cell line by peptide mapping.  Using a tryptic digest of either [3H]tyrosine- HURLEY  ET  AL.  485 
or [3H]phenylalanine-labeled molecules, both  the alpha and beta chains were 
virtually indistinguishable between MT2  and  DR  preparations.  Two of these 
comparisons are shown in Figs.  3 and 4. Only differences in the ratios of peak 
heights between the I-LR2 and L203 maps were observed. The additional peak 
observed around fraction 10 in the L203 preparation in Fig. 4 was not consist- 
ently present. Since the MT3 preparations were more complicated because both 
DR and DS molecules were present, a peptide map comparison was not made. 
Discussion 
A number of biochemical studies have had as their goal the molecular localiza- 
tion of HLA-D region-associated serologic specificities. Characterization of the 
molecules bearing these determinants is  important  in  defining the functional 
relevance of each of the multiple molecules controlled by this genetic region. 
One set of these serologic specificities resides on the DR- or I-E-like antigens. 10 
DR allelic products have been recognized; all of those studied express structurally 
distinct DR beta chains. Since there are several I-E-like molecules in a homozy- 
gous cell (10,  11),  it is unclear if all of these closely related molecules bear DR 
serologic determinants. In addition, it is not known if all cells bearing a particular 
DR allele express exactly the same set of DR molecules. For instance, in DR4- 
positive  cells,  the  DR  beta  chains  exhibit  variation  correlated with  HLA-D 
specificity (40), In general, therefore, a cell has several I-E-like molecules, all or 
some of which bear DR serologic specificities. 
Some of the HLA-D serologic specificities have been associated with more than 
one  DR  specificity and  have,  therefore, been  termed supertypic specificities. 
These specificities could represent either public determinants on DR molecules 
or determinants on unique molecules. The MB (DC) supertypic determinants 
appear to represent the latter.  Population studies had suggested that the MB 
specificities represented an  allelic  series  in  Hardy-Weinberg equilibrium  (3). 
Using monoclonal antibodies and alloantisera directed against  MB1  (DC1  or 
MT1) and MB3 determinants, these specificities were found to reside on mole- 
cules distinct from DR (13, 14, 41-43). These molecules, which are homologous 
to murine I-A, have been termed DS (12). These observations are in accord with 
evidence that expression of DR1 and MB1  could be separately eliminated from 
DR1,  MB1  cells by means of mutagenic treatment (31, 44). Although MB1,  2, 
and 3 are alleles, it now appears that variability exists within a set of molecules 
bearing a particular MB allelic specificity. That is, the DS molecule in DR4 cells 
may be structurally distinct from the DS molecule in DR5  cells although both 
molecules bear the MB3  specificity (32).  These differences may represent the 
DS allelic products observed by Goyert and Silver (45). While it is not conclusive 
that additional MB determinants will not be found on DR molecules, the simplest 
interpretation of the present data is  that  the MB supertypic series represents 
public determinants on DS or I-A-like molecules. 
A second group of supertypic specificities is the MT series. Two members of 
the MT series appear to be identical to previously described MB specificities on 
the basis of their DR-associated distribution. MT 1 appears to be indistinguishable 
from MB1  (DC1), and MT4 appears to be indistinguishable from MB3  (DC4) 
(See Table I). Thus, when ~/rays were used to eliminate expression of DR1 from 486  MOLECULAR LOCALIZATION  OF MT2 AND MT3 
a  DR1,  MB1,  MT1  lymphoblastoid cell  line,  those  mutants  that  continued  to 
express  MB1  also  expressed  MTI  (44).  MT2  and  MT3  have  clearly  distinct 
distributions  from the remainder  of the  MB specificities and  represent  unique 
serologic  determinants.  It  is  unclear  whether  MT2  and  MT3  are  allelic  or 
represent unrelated (i.e., nonallelic) serologic specificities. 
In the population studies presented here, MT2 and MT3 alloantisera reactivity 
paralleled the associated DR specificities. That is, all DR3, 5, and w6 individuals 
tested were MT2 positive, and almost all DR4, 7, and w9 individuals were MT3 
positive.  The  sole exception  is  DRw9, in  which  one of four individuals  tested 
was MT3 negative. This is in contrast to the MB3 supertypic specificity, which 
is also associated with DR5. Not all DR5 individuals are MB3 positive, as some 
exhibit other MB specificities. These observations could be explained if MT were 
a public determinant on DR molecules, in contrast to MB3, which is located on 
a molecule distinct from DR. 
To analyze the biochemical bases of the MT2 and MT3 serologic specificities, 
two monoclonal antibodies with MT specificity were identified by panel testing. 
Neither monoclonal antibody displayed a reactivity profile that exactly paralleled 
that obtained with standard alloantisera.  Correlation of I-LR2 and MT2 alloan- 
tisera was high although I-LR2 did not bind most MT2-positive DRw8 cells. The 
correlation  of  109d6  binding  with  MT3  reactivity  was  not  perfect  due  to 
reactivity of this monoclonal antibody with DRwl0-positive cells. This indicates 
that the reactivity of this monocional antibody was not identical with most of the 
usual  MT3  alloantisera,  further  emphasizing  the  complexity of determinants 
detected on HLA-D region products.  Excluding this,  every panel member who 
was MT3 positive was  109d6 positive. The reactivity with DRwl0 cells, which 
are negative  when  tested by MT3 alloantisera,  suggests that  the  109d6 deter- 
minant  is distinct from the MT3 determinant  but that its inheritance  is tightly 
linked to the inheritance  of the MT3 epitope, as would be expected for deter- 
minants on the same molecule or on molecules encoded by closely linked genes 
as are the HLA-D region  molecule.  Based on panel  testing and  family studies, 
therefore,  I-LR2 and  109d6 recognize  MT2- and  MT3-1ike determinants  with 
only a few discrepancies. 
A number of serologic determinants may comprise an MT specificity defined 
by alloantisera.  Since  the  monoclonal  antibodies  recognize  a  single  serologic 
determinant, it is possible that by using monoclonal antibodies, one is examining 
a  subset  of the  MT-bearing  molecules.  An  example  of this  is  illustrated  by 
I-LR2, which fails to recognize MT2-positive DRw8 cells. Alloantisera with this 
same  specificity would  be  called  "MT2  short."  In  addition,  the  determinant 
recognized by the monoclonal antibodies may be closely linked but not identical 
to  those  reactive  with  MT  alloantisera.  This  may be  the  case  for  the  109d6 
determinant,  as suggested by its DRw 10 reactivity. These questions were exam- 
ined by using the I-LR2 and  109d6 monoclonal antibodies to block MT-specific 
alloantisera.  Since I-LR2 partially blocks some MT2 alloantisera,  I-LR2 appears 
to recognize a secondary MT2 determinant. This determinant is absent in DRw8 
cells. 
MT3 alloantisera were not inhibited by 109d6 on the DR7 B cell line but two 
of the three  MT3 ailoantisera  were inhibited  by  109d6  on  the  DR4 cell  line. HURLEY  ET  AL.  487 
These results suggest that (a) some MT3 alloantisera  contain additional alioan- 
tibodies (such as DR7) that are not inhibited by 109d6 on the DR7 cell line, and/ 
or (b)  the  relationship  of the  109d6  determinant  to  the  MT3  determinant  is 
different in DR4 and DR7 cell lines. For example, MT3 aUoantisera may detect 
additional  MT3-bearing  molecules  on  the  DR7  cell  line,  not  recognized  by 
109d6, and these additional molecules are not present on the DR4 cell line. The 
109d6-blocking data, coupled with the population studies, suggests that  109d6 
recognizes a determinant adjacent to, but not identical to, the MT3 determinant 
recognized by alloantisera.  L203 was able to block all DR and MT alloantisera 
tested, suggesting that  molecules bearing MT and  DR determinants  also carry 
L203 determinants.  In our studies, the vast majority of these molecules are I-E- 
like.  These  studies  will  be expanded  upon  and  discussed  further  in  a  future 
publication. 
Both  I-LR2- and  109d6-reactive  DR  molecules appear  to  represent  only a 
portion of the L203-reactive DR pool. This has been suggested by experiments 
in  which eluates from an antibody affinity column are repassed over the same 
and complementary columns. A  similar result has been observed using another 
MT2-1ike monoclonal antibody by Koning et al. (34). 
A number of biochemical studies have attempted to define the structural bases 
of the MT2 and MT3 determinants.  Using alloantisera and two-dimensional gel 
analysis and peptide mapping, MT2 has been localized on DR molecules (19, 20, 
22) and on a molecule distinct from DR (20, 23). In one study, the new molecule, 
BR, was found to be closely related to the DR molecule, with a  DR alpha chain 
and a  similar beta chain  (20).  The definition  of "non-DR" molecules by many 
workers  who  use  alloantisera  is  often  based  on  "extra  spots"  seen  on  two- 
dimensional gels distinct from the spots defined by DR alloantisera. All of these 
molecules may be I-E-like and many have L203 epitopes on them. In the present 
study,  a  monoclonal  antibody was used  to  isolate  molecules bearing an  MT2 
determinant.  Amino acid sequence analysis and peptide mapping of these mole- 
cules revealed no differences between MT2-bearing molecules and DR- or L203- 
reactive molecules. Since L203 strongly inhibits MT2 alloantisera and it has been 
shown to recognize  DR-like molecules (28),  molecules carrying  MT2 determi- 
nants are obviously DR-like, but it is also possible that  these I-E-like molecules 
carrying  MT2 determinants  do not all carry DR allospecificities. At this point, 
we do not know precisely which of the many DR-like molecules in a  cell carry 
the DR allospecificities. It is possible that some of these may carry MT2-unique 
aliodeterminants  and not DR allodeterminants.  Since multiple serologic deter- 
minants can make up the MT2 specificity, this study can not determine if another 
MT2 determinant resides on non-DR molecules. A simplified model that explains 
much of the data is presented in Fig. 5. 
Previous studies have localized the MT3 epitope to DR (21), DS (21), or to a 
non-DR molecule, either  undefined (27, 46, 47) or BR (24, 48).  In our study, 
using a monoclonal antibody with a  MT3-1ike distribution identical to that used 
by Toguchi et al.  (27),  MT3-1ike determinants  were found to reside primarily 
on DR molecules although  DS molecules also bore the determinant.  A  similar 
result was observed by Goyert et al. (21) and Goyert and Silver (45). Sharing of 
serologic determinants  between the products of different loci (I-A and I-E) has 488  MOLECULAR LOCALIZATION OF MT2 AND MT3 
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FIGURE 5.  SchematicdiagramofthepossiblegeneticorganizationoftheHLA-DRsubregion. 
Evidence presented to date suggests that the DR or I-E-like molecules are encoded by a single 
alpha chain gene and multiple l-E-like beta chain genes within a haplotype. This study suggests 
that some but not all of these 1-E-like species bear MT serologic determinants. The results of 
this and  other studies suggest  that some  of the  I-E-like molecules also  bear DR  serologic 
determinants. All three of these subsets of I-E-like molecules may not exist in all cells. 
been previously observed in  the murine system (49).  Interestingly, one of the 
monoclonal antibodies directed against murine I-A and I-E antigens reacts with 
human cells in an MT-specific pattern (50). Sharing of determinants by different 
gene products of human class  II antigens has also been observed using other 
monoclonal antibodies such as I-LR1  (SB and DR) (16,  17) and CC11.23  and 
SG171  (DR  and  DS)  (21,  31).  Recently, Finn  et  al.  (51)  have described  the 
sharing of a common antigenic determinant between human DR and the invar- 
iant chain. 
The HLA-D region, therefore, encodes at  least three distinct molecules: (a) 
DR molecules, the predominant HLA-D molecules, bear homology to murine I- 
E antigens. Some or all of these I-E-like molecules bear the allele-specific DR 
serologic determinants as well as MT2- ~nd MT3-1ike public determinants (see 
Fig. 5). (b) DS molecules, murine I-A homologues, bear MB (DC) determinants 
and, in some instances, MT3-1ike determinants. (c) SB molecules, distinct from 
DR and DS and intermediate in structure between I-E and I-A, have not been 
defined using alloantisera.  A  fourth set of molecules, termed BR,  have been 
characterized by  peptide  mapping  in  other  studies  (20,  24,  48).  By  peptide 
mapping, these molecules exhibit homology with DR molecules and could rep- 
resent one of the multiple DR  subsets.  Evidence has been presented that  BR 
molecules do not carry DR determinants, but do bear MT2 or MT3 determinants 
(20,  24).  Further sequence analysis of the BR molecule should establish their 
relationship to  the  DR  molecules and should definitively establish  if a  fourth 
HLA-D subregion exists. 
The human HLA-D family of molecules presents an interesting example of 
the divergence of a  gene family creating an enormous amount of complexity 
while maintaining considerable homology. This  sharing of specific regions of 
molecules detected by alioantisera and monoclonal antibody reactivity presents HURLEY ET AL.  489 
interesting evolutionary questions. Two distinct issues, evident from the available 
serological and biochemical studies, almost defy explanation using conventional 
genetic models.  First,  at  least three  DR  beta chains are associated with  most 
specificities. The data presented here indicates that these beta chains are struc- 
turally distinct from haplotype to haplotype and yet, between alleles, they share 
public specificities (MT2 and MT3).  If, on the one hand, "triplication" of the 
beta chain loci occurred before the development of allospecificities (for example 
DR3 and DR5), it is hard to reconcile the presence of three unique beta chains 
with the sharing of specificities (for example MT2) on these same molecules. On 
the other hand, if triplication occurred after the development of the allospeci- 
ficities, one would have to postulate that the triplication occurred as an inde- 
pendent event at  least  10  times (to account for DR(w)  1-10).  Second, sets of 
genes must evolve in parallel so that, for example, DR4 and DS4 arise together 
as  unique  genes different from  DR5  and  DS5  (32).  Despite  this  divergence, 
molecules must maintain regions of homology so that DS4 and DS5 maintain a 
shared  region,  measured  serologically as  MB3.  DR3  and  DR5  maintain  the 
shared specificity MT2, and DR4 and DS4 maintain the shared specificity MT3. 
While maintenance of the latter could be evidence of gene conversion, other 
shared regions may be maintained by selective pressures possibly related to the 
functional importance of the determinants. 
Indeed,  MT  serologic  specificities  are  not  simple  serologic  anomalies  but 
appear to be important determinants in immune function. Several diseases show 
a strong association with MT specificities, for example, primary sicca syndrome 
with MT2 (52) and juvenile onset diabetes and rheumatoid arthritis in Japanese 
with MT3 (53, 54). In addition, the reactivities of some alloreactive lymphocyte 
clones have been directed towards MT determinants (55, 56), and some antigen- 
specific  T  lymphocyte responses  are  MT  restricted (57,  58).  The  functional 
relevance of the HLA-D molecules, therefore, appears to be controlled by the 
determinants localized on those molecules. Conversely, the molecular localization 
may affect the impact of those determinants in the immune response. It will be 
important in future functional studies to ascertain the precise HLA-D determi- 
nants involved in antigen and T  cell recognition and the molecular context in 
which those determinants are presented. 
Summary 
The specificities of the monoclonal antibodies I-LR2 and  109d6,  which rec- 
ognize  MT2-  and  MT3-1ike  serologic  determinants,  respectively,  have  been 
confirmed by panel testing. In addition, the relationships of these antibodies to 
other monoclonai antibodies and alloantisera have been studied by means of cell 
surface fluorescence, complement-dependent cytotoxicity and  immunoprecipi- 
tation.  Using these monoclonal antibodies,  molecules encoded by the HLA-D 
region  have  been  isolated  and  characterized  by  amino  acid  sequencing and 
peptide mapping. By these criteria, the major populations of molecules bearing 
MT2- and MT3-1ike determinants are indistinguishable from DR molecules. 
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